Health Care·Life Sciences Tools & Services·$8.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.53 | N/A | +4.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.53 | N/A | +4.94% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed satisfaction with the quarter's earnings performance. They emphasized their commitment to innovation as a key growth driver.
We are pleased with our performance this quarter.
Our focus on innovation continues to drive growth.
Charles River Laboratories reported a strong earnings per share, exceeding expectations, which contributed to an 8.86% increase in stock price. The positive stock reaction reflects investor confidence in the company's performance and management's focus on innovation. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018